TrialDiabetes, metabolic syndrome and obesity : targets and therapy2025

Effect of Imeglimin, a Novel Anti-Diabetic Agent, on Insulin Secretion and Glycemic Variability in Type 2 Diabetes Treated with DPP-4 Inhibitor: A 16-Week, Open Label, Pilot Study.

Atsushi Itsukaichi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.